Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: BuySellSignals Research
$5.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cipla Ltd Gets Relief In Patent Battle With Pfizer Inc-Business Standard


Monday, 11 Feb 2013 02:15pm EST 

The Business Standard reported that the patent office has again ruled in favour of Cipla, reinstating its earlier decision to revoke the Pfizer Inc’s patent for cancer drug Sutent in India. Following a post-grant opposition by Cipla in October last year, the patent controller had rejected Pfizer’s claim for the patent over Sutent. The patent regulator had said the claimed patent did not involve any inventive step. However, after the rejection, Pfizer appealed in the Supreme Court, which reinstated the patent and returned the case to the patent office for a fresh hearing. After the apex court sent the issue back to the patent controller, the multinational company approached the Delhi High Court seeking a stay on Cipla selling the drug. In December 2012, the court adjourned the case filed by Pfizer and decided to wait for the patent controller’s decision. 

Company Quote

435.75
0.75 +0.17%
11 Jul 2014